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346 The Journal of Thoracic and CardioObjective: Cardiopulmonary bypass is associated with systemic inflammatory re-
sponse syndrome and risk of multiorgan injury mediated by activated leukocytes.
Phosphodiesterase type 4 is the predominant phosphodiesterase isozyme in leuko-
cytes and plays a key role in the regulation of leukocyte activation. The aim of this
study was to examine the effect of rolipram, a selective phosphodiesterase type 4
inhibitor, on functional changes of monocytes during simulated extracorporeal
circulation.
Methods and Results: Simulated extracorporeal circulation was established by
recirculating heparinized human blood for 120 minutes on a membrane oxygenator
with or without 10 mol/L of rolipram. L-selectin and CD11b expression of
monocytes were measured with flow cytometry. C4d fragment, Bb fragment, C5b-9,
and interleukin-6 were measured with enzyme immunoassay. Rolipram reduced the
increase in CD11b expression and the decrease in L-selectin expression of mono-
cytes in response to simulated extracorporeal circulation. Rolipram inhibited the
increase in C4d fragment and interleukin-6, but it did not affect the increase in Bb
fragment or C5b-9.
Conclusion: Rolipram inhibited changes in adhesion molecule expression and in-
terleukin-6 release by activated monocytes in simulated extracorporeal circulation.
This study suggests that phosphodiesterase type 4 inhibition could be feasible
therapeutic strategy to prevent exaggerated inflammatory response and organ injury
in patients undergoing cardiopulmonary bypass.
Cardiopulmonary bypass (CPB) is associated with systemic inflammatoryresponse syndrome, in which patients are at risk for organ injury typical ofacute respiratory distress syndrome. It is well documented that this injury is
mediated by activated polymorphonuclear (PMN) leukocytes and monocytes.1-3
Monocytes are activated by both the direct contact with the synthetic surface and the
activated complements produced during CPB.1,2,4,5 Monocytes produce numerous
proinflammatory and anti-inflammatory cytokines including interleukins (ILs)-1, 2,
4, 6, 8, 10, and 12. Monocyte expression of CD11b increases to peak 24 hours after
CPB.2
We previously documented that a phosphodiesterase (PDE) type 4 inhibitor
inhibits the activation of PMN in a simulated extracorporeal circulation (SECC)
model.6 cAMP is an intracellular messenger that has a suppressant effect on
leukocyte activation.7 cAMP is inactivated by PDE, and PDE type 4 is the predom-
inant PDE isozyme in leukocytes.7 Specific PDE type 4 inhibitors increase cAMP
in leukocytes and are reported to inhibit increase of cytosolic calcium in stimulated
human leukocytes,8 a pivotal event in leukocyte activation.9 Therefore, inhibition of
PDE type 4 in SECC is considered to inhibit the activation of leukocytes through
cAMP. Furthermore, it is speculated that PDE type 4 inhibition inhibits monocyte
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Pactivation in SECC because cAMP also has a suppressant
effect on monocyte activation.7,10
Our working hypothesis is that PDE type 4 inhibitor
inhibits monocyte activation during CPB, which could lead
to reduction of the systemic inflammatory response and
prevention of organ injury related to CPB. We and others
used SECC extensively as an in vitro model of inflamma-
tory responses during in vivo CPB.6,11,12 This study evalu-
ated the effect of the PDE type 4 inhibitor rolipram on
monocyte activation during SECC. We evaluated the effect
of rolipram on complement activation, expression of adhe-
sion molecules, and release of IL-6 by monocytes.
Methods
Simulated Extracorporeal Circulation
The effect of extracorporeal circulation on the activation of leu-
kocytes was evaluated by using SECC as described previ-
ously.6,11,13 Each perfusion circuit (surface area 0.66 m2) was
assembled from Silastic tubing (0.25-inch inside diameter; MERA,
Tokyo, Japan), polycarbonate connectors, a polyvinyl chloride
venous reservoir bag (MERA), and a 0.6 m2 membrane oxygenator
(model 60EC; MERA). All components of the circuit were steril-
ized and used once. Human blood (250 mL) was drawn from
healthy male donors (age 25-40 years) through an 18-gauge needle
and polyvinyl tubing directly into a venous reservoir bag contain-
ing heparin (3.75 U/mL). Donors abstained from all medications
for at least 2 weeks before donation. Written informed consent was
obtained from all donors, and the protocol was approved by the
institutional review board of the University of Tsukuba.
The perfusion circuit was filled with blood (control group, n 
6) or blood containing rolipram (10 mol/L final concentration,
BIOMOL Research Laboratories, Inc, Plymouth Meeting, Pa)
(rolipram-treated group, n  6). Blood was recirculated with a
barely occlusive roller pump (model MS-033; MERA) at 400
mL/min for 120 minutes. Oxygenators were ventilated with 95%
oxygen and 5% carbon dioxide at a rate of 0.7 L/min. Blood
temperature was maintained at 37°C by immersing the reservoir
bag in a constant-temperature shaking water bath. Four blood
samples were drawn from the reservoir into polypropylene tubes
before recirculation (time zero) and 30, 60, and 120 minutes after
recirculation. The standing control sample (3.75 U/mL heparin)
was incubated for 120 minutes in a shaking water bath at 37°C
before processing. Blood samples for blood cell counts and dif-
ferential white cell counts were collected in tubes containing
potassium ethylene tetra acetic acid (VT-052DK, Venoject;
Terumo, Tokyo, Japan). Blood samples for CD11b and L-selectin
were collected into tubes containing acid-citrate-dextrose (9:1 by
volume). Blood samples for complement and IL-6 analysis were
collected and centrifuged at 3000 rpm for 15 minutes, and the
supernatant was stored at 80°C until measurement.
Blood Cell Counts
Blood cell counts were performed with a counter (T-660, Coulter
Electronics, Hialeah, Fla), and differential white cell counts were
performed on Wright’s-stained blood smears by an experienced
independent observer.
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Changes in the surface expression of L-selectin and CD11b on
monocytes were measured by flow cytometry as described previ-
ously.14 One-hundred microliters of whole-blood samples were
incubated for 30 minutes with 2 g/mL of fluorescein isothiocya-
nate-conjugated mouse monoclonal CD62L antibody (isotype
IgG1 kappa, Pharmingen, San Diego, Calif) and 1 g/mL phyco-
erythrin-conjugated mouse monoclonal antihuman CD11b anti-
body (isotype IgG1 kappa, DAKO Laboratories, Glostrup, Den-
mark) antibody or at 4°C. Identical samples were incubated with
fluorescein isothiocyanate-conjugated mouse immunoglobulin
(Ig)G (isotype IgG1 kappa, DAKO) and phycoerythrin-conjugated
mouse IgG (isotype IgG1 kappa, DAKO) as negative controls.
Erythrocytes were lysed for 60 seconds with Immuno-lyse, and
leukocytes were fixed with Immuno-fix (Coulter Clone kits,
Coulter Immuno, Hialeah, Fla). Monocytes were identified accord-
ing to the typical forward- and side-scatter pattern, and expression
of L-selectin and CD11b was measured simultaneously as the
mean fluorescence intensity of 3000 monocytes. Changes in L-
selectin and CD11b levels were expressed as percentage changes
compared with baseline values.
Serum Assays
To evaluate complement activation, C4d fragment, Bb fragment,
and C5b-9 (the terminal complement component) were measured
with enzyme-linked immunosorbent assay kits (Quidel Corpora-
tion, San Diego, Calif) according to the manufacturer’s instruc-
tions. IL-6 was measured with a high-sensitivity enzyme-linked
immunosorbent assay kit (AN’ALYZA IL-6 HS; Genzyme Tech,
Minneapolis, Minn) according to the manufacturer’s instructions.
Statistical Analysis
One-way analysis of variance compared with time 0 value was
used for within-group comparison. Two-way analysis of variance
with repeated measure was used for the comparison between
groups. The sequential rejective Bonferroni test was used to cor-
rect for multiple comparisons.15 All values are expressed as the
mean  standard error.
Results
Blood Cell Counts
The white blood cell count and hematocrit did not change
significantly in either group (data not shown). The mono-
cyte count did not change significantly in either group (313
 35 L to 252 25 L in the control group, 357 45 L
to 319  40 L in the rolipram group).
Adhesion Molecule Assays
Typical flow cytometry plots of the control group at 0 and
120 minutes, and the standing control, are shown in Figure
1. L-selectin and CD11b were stained simultaneously on
monocytes, and the mean fluorescent intensities were used
for the evaluation of changes of adhesion molecules. The
expression of L-selectin on monocytes decreased to 28.1%
 5.2% of the baseline value at 120 minutes in the control
group (Figure 2, A, P  .0001). Rolipram significantly
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baseline value at 120 minutes). The expression of CD11b on
monocytes increased to 301.7%  27.7% of the baseline
value at 120 minutes in the control group (Figure 2, B, P 
.0001). Rolipram significantly inhibited this increase (P 
.05, 188.2%  29.5% of the baseline value at 120 minutes).
Rolipram inhibited the change in adhesive quality of mono-
cytes induced by SECC.
Serum Assays
C4d fragment, an indicator of the classic complement path-
way,16 increased from 0.32  0.08 g/mL to 0.72  0.11
g/mL at 120 minutes in the control group (Figure 3, A,
P  .05). Rolipram significantly inhibited this increase
(P .01, 0.26 0.04 g/mL at 120 minutes). Bb fragment,
an indicator of the alternative complement pathway,17 in-
creased at 120 minutes in both the control group (Figure 3,
B, P  .05, 0.04  0.01 g/mL to 0.26  0.04 g/mL) and
the rolipram-treated group (P  .05, 0.04  0.01 g/mL to
0.25  0.02 g/mL). Rolipram did not alter this increase in
Bb fragment. C5b-9, a terminal complement complex that
mediates irreversible membrane damage of target cells,18
increased at 120 minutes in both the control group (Figure
3, C, P  .001, 121.2  42.1 g/mL to 1190.5  149.4
g/mL) and the rolipram-treated group (P  .005, 73.7 
4.4 g/mL to 1259.7  254.8 g/mL). Rolipram did not
alter this increase in C5b-9. IL-6, an inflammatory cytokine
released predominantly from monocytes, increased from
0.96  0.26 g/mL to 7.80  0.95 g/mL at 120 minutes
in the control group (Figure 4, P  .0001). Rolipram
significantly inhibited this increase (P  .001, 1.25  0.44
g/mL at 120 minutes).
Discussion
Systemic inflammatory response syndrome is a major cause
Figure 1. Typical flow cytometry plots of control group
and CD11b were stained simultaneously on monocyte
evaluation of changes of adhesion molecules.at 0 and 120 minutes, and standing control (SC). L-selectin
s, and the mean fluorescent intensities were used for theof complication of CPB, and activated monocytes play an
348 The Journal of Thoracic and Cardiovascular Surgery ● AuguFigure 2. Expression of L-selectin and CD11b on monocytes. A,
Expression of L-selectin on monocytes decreased in both control
and rolipram-treated groups. Rolipram attenuated this decrease.
Results are expressed as mean  standard error of mean (SEM)
of 6 experiments. *P < .0001 versus baseline. **P < .05 versus
control. B, Expression of CD11b on monocytes increased in both
control and rolipram-treated groups. Rolipram inhibited this in-
crease. Results are expressed as mean  SEM of 6 experiments.
*P < .0001 versus baseline. **P < .05 versus control.
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Pimportant role in this response associated with CPB.1-3
Monocytes are activated by direct contact with synthetic
Figure 3. C4d fragment, Bb fragment, and C5b-9 concentrations.
A, C4d fragment, an indicator of the classic complement pathway,
increased in the control group. Rolipram inhibited this increase.
Results are expressed as mean SEM of 6 experiments. *P< .05
versus baseline. **P < .01 versus control. B, Bb fragment, an
indicator of the alternative complement pathway, increased in
both control and rolipram-treated groups. Rolipram did not alter
this increase. Results are expressed as mean  SEM of 6 exper-
iments. *P< .05 versus baseline. C, C5b-9, a terminal complement
complex, increased in both control and rolipram-treated groups.
Rolipram did not alter this increase. Results are expressed as
mean  SEM of 6 experiments. *P < .005 versus baseline.surface, activated complement, and heat shock proteins pro-
The Journal of Thoraciduced during CPB.1,2,4 Our results show that a selective
PDE type 4 inhibitor rolipram inhibits the activation of
monocytes induced by SECC. This was associated with
inhibitions of the decrease in L-selectin expression, the
increase in CD11b expression, and the release of IL-6 from
monocytes. These phenotypic and functional characteristics
of monocytes have all been shown to affect leukocyte-
mediated organ injury.19,20
SECC decreased L-selectin expression on monocytes
(Figure 2, A). This is consistent with observations of PMN
in former SECC studies.6 SECC increased the expression of
CD11b on monocytes (Figure 2, B), which is consistent with
previous SECC studies21-23 and most clinical studies.3,24
CPB induces complement activation through both the
classic and alternative pathways.2,25 Activated complement
components are major contributors to monocyte activation
induced during SECC.12,21 SECC induced complement ac-
tivation of both the classic and alternative pathways, as
shown by the increase in C4d fragment (Figure 3, A) and Bb
fragment (Figure 3, B), respectively. Rolipram inhibited the
increase in C4d fragment but did not alter the increase in Bb
fragment. It is not clear from our data why rolipram inhib-
ited activation of the classic pathway. C1q, the initial com-
ponent of the classic complement pathway, interacts with
several immunologically important cell types, including
lymphocytes, monocytes, and PMN.26 PDE type 4 inhibi-
tors inhibit the functions not only of PMN6,27 but also of
monocytes10 and lymphocytes.28,29 Inhibition of the activa-
tion of these leukocytes by rolipram may have resulted in
Figure 4. IL-6 concentration. IL-6 increased in both control and
rolipram-treated groups. Rolipram inhibited this increase. Results
are expressed as mean  SEM of 6 experiments. *P < .0001
versus baseline, **P < .001 versus control. IL, Interleukin.inhibition of the interaction with C1q and activation of the
c and Cardiovascular Surgery ● Volume 130, Number 2 349
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plement component, and rolipram did not alter this increase
(Figure 3, C). Although rolipram inhibited activation of the
classic pathway, it failed to inhibit activation of alternative
pathway and the terminal complement component.
SECC induced the release of IL-6 from monocytes (Fig-
ure 4), and rolipram inhibited this release. CPB induces an
inflammatory response and the release of inflammatory cy-
tokines.2 In blood cells, monocytes are the predominant
source of cytokines and are known to release numerous
inflammatory cytokines in response to CPB.2 The release of
these cytokines from monocytes could cause activation of
PMN and endothelial cells, resulting in tissue injury.25 Our
results suggest that rolipram inhibits organ injury by inhib-
iting monocytes activation and cytokine production. How-
ever, in clinical application of PDE type 4 inhibitor, it is
possible that PDE type 4 inhibitors cause peripheral vaso-
dilation and hypotension, because PDE type 4 inhibitors
also distribute in smooth muscle cells.
In summary, this study showed that the selective PDE
type 4 inhibitor rolipram inhibits functional changes of
monocytes in an SECC model that mimics inflammatory
responses to CPB. Rolipram also inhibits IL-6 release from
monocytes, which may enhance inflammatory response.
Thus, PDE 4 inhibition is a potential therapeutic strategy for
the prevention of exaggerated inflammatory response and
organ injury related to CPB.
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